Drug intelligence / Profile preview

miR-29b mimic

Development stage: Preclinical
Modality: RNA Therapeutics → Nucleic Acid Therapeutics

Overview

miR-29b mimic is a microRNA mimic designed to increase the levels of microRNA-29b. In colon cancer, overexpression of miR-29b has been shown to inhibit cell growth, promote sensitivity to oxaliplatin (L-OHP), and stimulate cell apoptosis. This is achieved by directly targeting and negatively regulating Folate Receptor 1 (FOLR1). Additionally, miR-29b mimic decreases the levels of ATP Binding Cassette Subfamily G Member 2 (ABCG2) and p-glycoprotein (p-gp) in cancer cells, which are associated with drug resistance.

Other names: microRNA-29bmicroRNA29bmicroRNA 29bhsa-miR-29bhsa-miR29bhsa-miR 29b

Targets

FOLR1 (FRα)

Beyond the preview

Go deeper on miR-29b mimic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on miR-29b mimic.

Explore the full profile